Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Hengrui’s SHR‑1826 ADC Earns Breakthrough Therapy Designation for c‑Met Overexpressed NSCLC

Fineline Cube Jan 13, 2026
Company Drug

Hengrui’s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China

Fineline Cube Jan 13, 2026
Company

MSD Reports Strong Global Sales Growth in 2024, Despite China Challenges

Fineline Cube Feb 6, 2025

US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) released its Q4 2024 financial report,...

Company

Amgen Reports Strong Q4 and Full-Year 2024 Sales Growth

Fineline Cube Feb 6, 2025

Amgen (NASDAQ: AMGN) released its Q4 2024 financial results this week, reporting USD 33.42 billion...

Company

Novo Nordisk Reports Soaring Global Sales in 2024, Driven by Diabetes and Obesity Care

Fineline Cube Feb 6, 2025

Denmark’s Novo Nordisk (CPH: NOVO-B) reported this week that its global sales during 2024 reached...

Company Drug

Astellas Pharma Submits NDA for Avacincaptad Pegol in Japan for Geographic Atrophy

Fineline Cube Feb 6, 2025

Japan-based major Astellas Pharma (TYO: 4503) announced that it has submitted a New Drug Application...

Company Drug

Roche’s Susvimo Approved by FDA for Diabetic Macular Edema

Fineline Cube Feb 6, 2025

Swiss pharmaceutical giant Roche (SWX: ROG) announced that it has received approval from the US...

Company Drug

FDA Approves Enhertu for HER2-Low and HER2-UltraLow Breast Cancer

Fineline Cube Feb 6, 2025

The US Food and Drug Administration (FDA) has approved Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody...

Company Deals

Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study

Fineline Cube Feb 6, 2025

Nanjing-headquartered Immunophage Biotech Co., Ltd., a targeted therapy developer with operations in China, Australia, and...

Company Drug

Betta Pharmaceuticals Gains NMPA Approval for BPI-452080 Clinical Study

Fineline Cube Feb 6, 2025

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received approval from the...

Company Drug

Haisco’s HSK39004 Gains NMPA Approval for COPD Clinical Trials

Fineline Cube Feb 6, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...

Company Medical Device

Sino Medical Sciences’ NC Rockstar Catheter Gains MDA Approval in Malaysia

Fineline Cube Feb 6, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...

Company Deals

Henan Lingrui to Acquire Yingu Pharma for RMB 704 Million

Fineline Cube Feb 6, 2025

China’s Henan Lingrui Pharmaceutical Co., Ltd. (SHA: 600285) announced plans to acquire a 90% ownership...

Company Drug

Junshi Biosciences Receives NMPA Approval for JS213 Clinical Trials

Fineline Cube Feb 6, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...

Company Drug

Beijing Biostar’s Utidelone Gains FDA Approval for Global Phase II/III Study

Fineline Cube Feb 6, 2025

China’s Beijing Biostar Technologies Ltd (HKG: 2563) announced that it has received approval from the...

Company Deals

ClouDr Group Integrates DeepSeeker R1 into CloudrBrain to Boost Chronic Disease Management

Fineline Cube Feb 6, 2025

China-based ClouDr Group Limited (HKG: 9955) announced the integration of the DeepSeeker R1 model into...

Company

Henlius’ Serplulimab Receives EU Approval for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Feb 6, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received marketing approval from...

Company Drug

Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378

Fineline Cube Feb 6, 2025

China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National...

Company Deals

Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms

Fineline Cube Feb 5, 2025

China-based Tofflon Science and Technology Group Co., Ltd. (SHE: 300171), a total solution service provider...

Company Deals

Becton Dickinson Considers Spinning Off Life Sciences Division

Fineline Cube Feb 5, 2025

US-based Becton, Dickinson and Co. (BD) is reportedly considering spinning off its life sciences division,...

Company Deals

Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition

Fineline Cube Feb 5, 2025

Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone...

Company Deals

Nona Biosciences Partners with Invetx for Animal Health Therapies

Fineline Cube Feb 5, 2025

Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership...

Posts pagination

1 … 161 162 163 … 608

Recent updates

  • Hengrui’s SHR‑1826 ADC Earns Breakthrough Therapy Designation for c‑Met Overexpressed NSCLC
  • Hengrui’s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China
  • Merck and Abbisko’s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval
  • Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share
  • FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra‑Rare Copper Deficiency Disorder
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s SHR‑1826 ADC Earns Breakthrough Therapy Designation for c‑Met Overexpressed NSCLC

Company Drug

Hengrui’s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China

Company Drug

Merck and Abbisko’s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.